Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial

Projekt

Ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation for elderly patients with lymphoma in relapse or resistant to chemotherapy. A multicenter phase I trial

Abgeschlossen · 2006 bis 2010

Hitz Felicitas, Demmer-Steingruber Ruth

Art

Klinische Forschung

Reichweite

Multizentrisch, KSSG als teilnehmendes Zentrum

Bereiche

Medizinische Onkologie und Hämatologie

Status

Abgeschlossen

Start

2006

Ende

2010

Finanzierungsart

Andere

Studiendesign

multicenter phase I trial that will include a minimum of 3 and a maximum of 24 patients

Schlagwörter (Tags)

maximum tolerated dose (MTD), chemotherapy resistant CD20+ lymphoma

Projektpartner

Dr. med. Michèle Voegeli Kantonsspital Liestal

Kurzbeschreibung/Zielsetzung

Identification of the maximum tolerated dose (MTD) of melphalan in combination with ibritumomab tiuxetan in patients ≥ 65 years with relapsed or chemotherapy resistant CD20+ lymphoma.
Evaluation of feasibility and safety of ibritumomab tiuxetan and high-dose melphalan as conditioning regimen before autologous stem cell transplantation in the same patient population.
Additional research question: Feasibility of stem cell mobilization with vinorelbine in patients ≥ 65 years with lymphoma after salvage treatment.